Journal Home
Search for

Volume 46, Issue 4, Pages 367-370 (December 2009)


View previous. 16 of 25 View next.

Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA

Silvia Baroncelli, Clementina Maria Galluzzo, Maria Franca Pirillo, Maria Grazia Mancini, Liliana Elena Weimer, Mauro Andreotti, Roberta Amici, Stefano Vella, Marina Giuliano, Lucia PalmisanoCorresponding Author Informationemail address

Received 18 June 2009; received in revised form 31 August 2009; accepted 10 September 2009. published online 27 September 2009.

Abstract 

Background

Recent data have shown that plasma levels of lipopolysaccharide (LPS) are a quantitative indicator of microbial translocation in HIV infected individuals.

Objectives

To assess the impact of residual viral replication on plasma LPS in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA and to evaluate LPS changes during repeated HAART interruptions not exceeding 2-month duration.

Study design

LPS was measured in 44 HIV+ subjects at T0 (during HAART) and at day 15 of the first and fourth HAART interruption. Ten uninfected, healthy donors were studied as well. Residual plasma HIV-1 RNA was measured at T0 by an ultra-ultrasensitive method with limit of detection of 2.5copies HIV-1 RNA/ml. Subjects with less than 2.5copies/ml (fully suppressed – FS) were compared to those with 2.5–50copies/ml (partially suppressed – PS).

Results

At T0, plasma LPS levels were comparable in FS and uninfected subjects, whereas in PS they were higher than in uninfected subjects (p=0.049). After 4 HAART interruptions, they did not change significantly. However, LPS values were lower in FS than in PS (p=0.020). An inverse correlation was found between CD4 and LPS levels (p=0.044) in PS group only.

Conclusions

A reduced degree of microbial translocation was seen in subjects with a more complete suppression of viral replication. Repeated HAART interruptions had no significant impact on plasma LPS levels.

Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy

Corresponding Author InformationCorresponding author at: Pharmacology and Therapy of Viral Disease Unit, Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. Tel.: +39 06 4938 4021; fax: +39 06 4938 7199.

PII: S1386-6532(09)00427-2

doi:10.1016/j.jcv.2009.09.011


View previous. 16 of 25 View next.